Pharmacokinetics in wistar rats of 5-[(4-carboxybutanoyl)amino]-2-hydroxybenzoic acid: A novel synthetic derivative of 5-aminosalicylic acid (5-ASA) with possible anti-inflammatory activity

Aurelio Romero-Castro, Mara Gutiérrez-Sánchez, José Correa-Basurto, Martha Cecilia Rosales Hernández, Itzia Irene Padilla Martínez, Jessica Elena Mendieta-Wejebe

Research output: Contribution to journalArticle

Abstract

© 2016 Romero-Castro et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 5-[(4-carboxybutanoyl)amino]-2-hydroxybenzoic acid (C.2) is a novel synthetic derivative of 5-aminosalicylic acid (5-ASA), which is currently being evaluated ex vivo as an anti-inflammatory agent and has shown satisfactory results. This study aimed to obtain the pharmacokinetic profiles, tissue distribution and plasma protein binding of C2 in Wistar Rats. Additionally, an HPLC method was developed and validated to quantify C2 in rat plasma. The pharmacokinetic profiles of intragastric, intravenous and intraperitoneal administration routes at singles doses of 100, 50, and 100 mg/kg, respectively, were studied in Wistar rats. The elimination half-life of intravenously administered C2 was approximately 33 min. The maximum plasma level of C2 was reached approximately 24 min after intragastric administration, with a Cmax value of 2.5 g/mL and an AUCtot value of 157 μgmin-1 /mL; the oral bioavailability was approximately 13%. Following a single intragastric or oral dose (100 mg/kg), C2 was distributed and detected in all examined tissues (including the brain and colon). The results showed that C2 accumulates over time. The plasma protein binding results indicated that the unbound fraction of C2 at concentrations of 1 to 20 μg/mL ranged from 89.8% to 92.5%, meaning that this fraction of C2 is available to cross tissues. Finally, the blood-plasma partitioning (BP ratio) of C2 in rat plasma was 0.71 and 0.6 at concentrations of 5 and 10 μg/mL, respectively, which indicates that C2 is free in the plasmatic phase and not inside blood cells. The results of this study suggest that a fraction of the administered C2 dose is absorbed in the stomach, and the fraction that is not absorbed reaches the small intestine and colon. This distribution
Original languageAmerican English
JournalPLoS ONE
DOIs
StatePublished - 1 Jul 2016

Fingerprint

Mesalamine
Pharmacokinetics
Salicylic Acid
anti-inflammatory activity
phenolic acids
pharmacokinetics
Wistar Rats
Rats
Anti-Inflammatory Agents
chemical derivatives
intragastric administration
Derivatives
Plasmas
acids
protein binding
rats
Tissue
Protein Binding
blood proteins
colon

Cite this

@article{4e8b3b259c7c4eea91cfd9b7df206d9a,
title = "Pharmacokinetics in wistar rats of 5-[(4-carboxybutanoyl)amino]-2-hydroxybenzoic acid: A novel synthetic derivative of 5-aminosalicylic acid (5-ASA) with possible anti-inflammatory activity",
abstract = "{\circledC} 2016 Romero-Castro et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 5-[(4-carboxybutanoyl)amino]-2-hydroxybenzoic acid (C.2) is a novel synthetic derivative of 5-aminosalicylic acid (5-ASA), which is currently being evaluated ex vivo as an anti-inflammatory agent and has shown satisfactory results. This study aimed to obtain the pharmacokinetic profiles, tissue distribution and plasma protein binding of C2 in Wistar Rats. Additionally, an HPLC method was developed and validated to quantify C2 in rat plasma. The pharmacokinetic profiles of intragastric, intravenous and intraperitoneal administration routes at singles doses of 100, 50, and 100 mg/kg, respectively, were studied in Wistar rats. The elimination half-life of intravenously administered C2 was approximately 33 min. The maximum plasma level of C2 was reached approximately 24 min after intragastric administration, with a Cmax value of 2.5 g/mL and an AUCtot value of 157 μgmin-1 /mL; the oral bioavailability was approximately 13{\%}. Following a single intragastric or oral dose (100 mg/kg), C2 was distributed and detected in all examined tissues (including the brain and colon). The results showed that C2 accumulates over time. The plasma protein binding results indicated that the unbound fraction of C2 at concentrations of 1 to 20 μg/mL ranged from 89.8{\%} to 92.5{\%}, meaning that this fraction of C2 is available to cross tissues. Finally, the blood-plasma partitioning (BP ratio) of C2 in rat plasma was 0.71 and 0.6 at concentrations of 5 and 10 μg/mL, respectively, which indicates that C2 is free in the plasmatic phase and not inside blood cells. The results of this study suggest that a fraction of the administered C2 dose is absorbed in the stomach, and the fraction that is not absorbed reaches the small intestine and colon. This distribution",
author = "Aurelio Romero-Castro and Mara Guti{\'e}rrez-S{\'a}nchez and Jos{\'e} Correa-Basurto and Hern{\'a}ndez, {Martha Cecilia Rosales} and Mart{\'i}nez, {Itzia Irene Padilla} and Mendieta-Wejebe, {Jessica Elena}",
year = "2016",
month = "7",
day = "1",
doi = "10.1371/journal.pone.0159889",
language = "American English",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",

}

Pharmacokinetics in wistar rats of 5-[(4-carboxybutanoyl)amino]-2-hydroxybenzoic acid: A novel synthetic derivative of 5-aminosalicylic acid (5-ASA) with possible anti-inflammatory activity. / Romero-Castro, Aurelio; Gutiérrez-Sánchez, Mara; Correa-Basurto, José; Hernández, Martha Cecilia Rosales; Martínez, Itzia Irene Padilla; Mendieta-Wejebe, Jessica Elena.

In: PLoS ONE, 01.07.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetics in wistar rats of 5-[(4-carboxybutanoyl)amino]-2-hydroxybenzoic acid: A novel synthetic derivative of 5-aminosalicylic acid (5-ASA) with possible anti-inflammatory activity

AU - Romero-Castro, Aurelio

AU - Gutiérrez-Sánchez, Mara

AU - Correa-Basurto, José

AU - Hernández, Martha Cecilia Rosales

AU - Martínez, Itzia Irene Padilla

AU - Mendieta-Wejebe, Jessica Elena

PY - 2016/7/1

Y1 - 2016/7/1

N2 - © 2016 Romero-Castro et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 5-[(4-carboxybutanoyl)amino]-2-hydroxybenzoic acid (C.2) is a novel synthetic derivative of 5-aminosalicylic acid (5-ASA), which is currently being evaluated ex vivo as an anti-inflammatory agent and has shown satisfactory results. This study aimed to obtain the pharmacokinetic profiles, tissue distribution and plasma protein binding of C2 in Wistar Rats. Additionally, an HPLC method was developed and validated to quantify C2 in rat plasma. The pharmacokinetic profiles of intragastric, intravenous and intraperitoneal administration routes at singles doses of 100, 50, and 100 mg/kg, respectively, were studied in Wistar rats. The elimination half-life of intravenously administered C2 was approximately 33 min. The maximum plasma level of C2 was reached approximately 24 min after intragastric administration, with a Cmax value of 2.5 g/mL and an AUCtot value of 157 μgmin-1 /mL; the oral bioavailability was approximately 13%. Following a single intragastric or oral dose (100 mg/kg), C2 was distributed and detected in all examined tissues (including the brain and colon). The results showed that C2 accumulates over time. The plasma protein binding results indicated that the unbound fraction of C2 at concentrations of 1 to 20 μg/mL ranged from 89.8% to 92.5%, meaning that this fraction of C2 is available to cross tissues. Finally, the blood-plasma partitioning (BP ratio) of C2 in rat plasma was 0.71 and 0.6 at concentrations of 5 and 10 μg/mL, respectively, which indicates that C2 is free in the plasmatic phase and not inside blood cells. The results of this study suggest that a fraction of the administered C2 dose is absorbed in the stomach, and the fraction that is not absorbed reaches the small intestine and colon. This distribution

AB - © 2016 Romero-Castro et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 5-[(4-carboxybutanoyl)amino]-2-hydroxybenzoic acid (C.2) is a novel synthetic derivative of 5-aminosalicylic acid (5-ASA), which is currently being evaluated ex vivo as an anti-inflammatory agent and has shown satisfactory results. This study aimed to obtain the pharmacokinetic profiles, tissue distribution and plasma protein binding of C2 in Wistar Rats. Additionally, an HPLC method was developed and validated to quantify C2 in rat plasma. The pharmacokinetic profiles of intragastric, intravenous and intraperitoneal administration routes at singles doses of 100, 50, and 100 mg/kg, respectively, were studied in Wistar rats. The elimination half-life of intravenously administered C2 was approximately 33 min. The maximum plasma level of C2 was reached approximately 24 min after intragastric administration, with a Cmax value of 2.5 g/mL and an AUCtot value of 157 μgmin-1 /mL; the oral bioavailability was approximately 13%. Following a single intragastric or oral dose (100 mg/kg), C2 was distributed and detected in all examined tissues (including the brain and colon). The results showed that C2 accumulates over time. The plasma protein binding results indicated that the unbound fraction of C2 at concentrations of 1 to 20 μg/mL ranged from 89.8% to 92.5%, meaning that this fraction of C2 is available to cross tissues. Finally, the blood-plasma partitioning (BP ratio) of C2 in rat plasma was 0.71 and 0.6 at concentrations of 5 and 10 μg/mL, respectively, which indicates that C2 is free in the plasmatic phase and not inside blood cells. The results of this study suggest that a fraction of the administered C2 dose is absorbed in the stomach, and the fraction that is not absorbed reaches the small intestine and colon. This distribution

U2 - 10.1371/journal.pone.0159889

DO - 10.1371/journal.pone.0159889

M3 - Article

C2 - 27454774

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

ER -